A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups

Gabriella Macchia, Roberta Lazzari, Nicoletta Colombo, Concetta Laliscia, Giovanni Capelli, Giuseppe Roberto D'Agostino, Francesco Deodato, Ernesto Maranzano, Edy Ippolito, Sara Ronchi, Fabiola Paiar, Marta Scorsetti, Savino Cilla, Rossana Ingargiola, Alessandra Huscher, Anna Maria Cerrotta, Andrei Fodor, Lisa Vicenzi, Donatella Russo, Simona BorghesiElisabetta Perrucci, Sandro Pignata, Cynthia Aristei, Alessio Giuseppe Morganti, Giovanni Scambia, Vincenzo Valentini, Barbara Alicja Jereczek-Fossa, Gabriella Ferrandina

Research output: Contribution to journalArticle

Abstract

Background: Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC). Materials and Methods: The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on “per-lesion” basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes. Results: CR, PR, and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of 96.4%. Patient aged ≤60 years, planning target volume (PTV) ≤18 cm3, lymph node disease, and biologically effective dose α/β10 > 70 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range, 3–120), the 24-month actuarial LC rate was 81.9%. Achievement of CR and total dose >25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7%) patients; of 63 side effects, 48 were grade 1, and 15 were grade 2. The 24-month late toxicity-free survival rate was 95.1%. Conclusions: This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate. Implications for Practice: This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age 70 Gy were associated with higher chance of complete response (CR). Achievement of CR and total dose >25 Gy were associated with better local control (LC) rate. Mild toxicity was experienced in 20.7% of patients. In conclusion, this study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.
Original languageEnglish
JournalOncologist
DOIs
Publication statusPublished - 2020

Fingerprint

Radiosurgery
Ovarian Neoplasms
Multicenter Studies
Retrospective Studies
Safety
Multivariate Analysis
Survival
Prostatic Neoplasms
Radiation Oncology
Therapeutics
Terminology
Non-Small Cell Lung Carcinoma
Androgens
Disease-Free Survival
Radiotherapy
Survival Rate
Logistic Models
Lymph Nodes
Organizations
Research

Keywords

  • Oligometastasis
  • Oligorecurrences
  • Ovarian cancer
  • Personalized medicine
  • Stereotactic body radiotherapy
  • Stereotactic radiosurgery

Cite this

A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study) : A Collaboration of MITO, AIRO GYN, and MaNGO Groups. / Macchia, Gabriella; Lazzari, Roberta; Colombo, Nicoletta; Laliscia, Concetta; Capelli, Giovanni; D'Agostino, Giuseppe Roberto; Deodato, Francesco; Maranzano, Ernesto; Ippolito, Edy; Ronchi, Sara; Paiar, Fabiola; Scorsetti, Marta; Cilla, Savino; Ingargiola, Rossana; Huscher, Alessandra; Cerrotta, Anna Maria; Fodor, Andrei; Vicenzi, Lisa; Russo, Donatella; Borghesi, Simona; Perrucci, Elisabetta; Pignata, Sandro; Aristei, Cynthia; Morganti, Alessio Giuseppe; Scambia, Giovanni; Valentini, Vincenzo; Jereczek-Fossa, Barbara Alicja; Ferrandina, Gabriella.

In: Oncologist, 2020.

Research output: Contribution to journalArticle

Macchia, G, Lazzari, R, Colombo, N, Laliscia, C, Capelli, G, D'Agostino, GR, Deodato, F, Maranzano, E, Ippolito, E, Ronchi, S, Paiar, F, Scorsetti, M, Cilla, S, Ingargiola, R, Huscher, A, Cerrotta, AM, Fodor, A, Vicenzi, L, Russo, D, Borghesi, S, Perrucci, E, Pignata, S, Aristei, C, Morganti, AG, Scambia, G, Valentini, V, Jereczek-Fossa, BA & Ferrandina, G 2020, 'A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups', Oncologist. https://doi.org/10.1634/theoncologist.2019-0309
Macchia, Gabriella ; Lazzari, Roberta ; Colombo, Nicoletta ; Laliscia, Concetta ; Capelli, Giovanni ; D'Agostino, Giuseppe Roberto ; Deodato, Francesco ; Maranzano, Ernesto ; Ippolito, Edy ; Ronchi, Sara ; Paiar, Fabiola ; Scorsetti, Marta ; Cilla, Savino ; Ingargiola, Rossana ; Huscher, Alessandra ; Cerrotta, Anna Maria ; Fodor, Andrei ; Vicenzi, Lisa ; Russo, Donatella ; Borghesi, Simona ; Perrucci, Elisabetta ; Pignata, Sandro ; Aristei, Cynthia ; Morganti, Alessio Giuseppe ; Scambia, Giovanni ; Valentini, Vincenzo ; Jereczek-Fossa, Barbara Alicja ; Ferrandina, Gabriella. / A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study) : A Collaboration of MITO, AIRO GYN, and MaNGO Groups. In: Oncologist. 2020.
@article{39ced87e32e04030adce8260c7404957,
title = "A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study): A Collaboration of MITO, AIRO GYN, and MaNGO Groups",
abstract = "Background: Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC). Materials and Methods: The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on “per-lesion” basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes. Results: CR, PR, and SD were observed in 291 (65.2{\%}), 106 (23.8{\%}), and 33 (7.4{\%}) lesions, giving a rate of CB of 96.4{\%}. Patient aged ≤60 years, planning target volume (PTV) ≤18 cm3, lymph node disease, and biologically effective dose α/β10 > 70 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range, 3–120), the 24-month actuarial LC rate was 81.9{\%}. Achievement of CR and total dose >25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7{\%}) patients; of 63 side effects, 48 were grade 1, and 15 were grade 2. The 24-month late toxicity-free survival rate was 95.1{\%}. Conclusions: This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate. Implications for Practice: This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age 70 Gy were associated with higher chance of complete response (CR). Achievement of CR and total dose >25 Gy were associated with better local control (LC) rate. Mild toxicity was experienced in 20.7{\%} of patients. In conclusion, this study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.",
keywords = "Oligometastasis, Oligorecurrences, Ovarian cancer, Personalized medicine, Stereotactic body radiotherapy, Stereotactic radiosurgery",
author = "Gabriella Macchia and Roberta Lazzari and Nicoletta Colombo and Concetta Laliscia and Giovanni Capelli and D'Agostino, {Giuseppe Roberto} and Francesco Deodato and Ernesto Maranzano and Edy Ippolito and Sara Ronchi and Fabiola Paiar and Marta Scorsetti and Savino Cilla and Rossana Ingargiola and Alessandra Huscher and Cerrotta, {Anna Maria} and Andrei Fodor and Lisa Vicenzi and Donatella Russo and Simona Borghesi and Elisabetta Perrucci and Sandro Pignata and Cynthia Aristei and Morganti, {Alessio Giuseppe} and Giovanni Scambia and Vincenzo Valentini and Jereczek-Fossa, {Barbara Alicja} and Gabriella Ferrandina",
year = "2020",
doi = "10.1634/theoncologist.2019-0309",
language = "English",
journal = "Oncologist",
issn = "1083-7159",
publisher = "Wiley Blackwell",

}

TY - JOUR

T1 - A Large, Multicenter, Retrospective Study on Efficacy and Safety Of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Ovarian Cancer (MITO RT1 Study)

T2 - A Collaboration of MITO, AIRO GYN, and MaNGO Groups

AU - Macchia, Gabriella

AU - Lazzari, Roberta

AU - Colombo, Nicoletta

AU - Laliscia, Concetta

AU - Capelli, Giovanni

AU - D'Agostino, Giuseppe Roberto

AU - Deodato, Francesco

AU - Maranzano, Ernesto

AU - Ippolito, Edy

AU - Ronchi, Sara

AU - Paiar, Fabiola

AU - Scorsetti, Marta

AU - Cilla, Savino

AU - Ingargiola, Rossana

AU - Huscher, Alessandra

AU - Cerrotta, Anna Maria

AU - Fodor, Andrei

AU - Vicenzi, Lisa

AU - Russo, Donatella

AU - Borghesi, Simona

AU - Perrucci, Elisabetta

AU - Pignata, Sandro

AU - Aristei, Cynthia

AU - Morganti, Alessio Giuseppe

AU - Scambia, Giovanni

AU - Valentini, Vincenzo

AU - Jereczek-Fossa, Barbara Alicja

AU - Ferrandina, Gabriella

PY - 2020

Y1 - 2020

N2 - Background: Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC). Materials and Methods: The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on “per-lesion” basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes. Results: CR, PR, and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of 96.4%. Patient aged ≤60 years, planning target volume (PTV) ≤18 cm3, lymph node disease, and biologically effective dose α/β10 > 70 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range, 3–120), the 24-month actuarial LC rate was 81.9%. Achievement of CR and total dose >25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7%) patients; of 63 side effects, 48 were grade 1, and 15 were grade 2. The 24-month late toxicity-free survival rate was 95.1%. Conclusions: This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate. Implications for Practice: This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age 70 Gy were associated with higher chance of complete response (CR). Achievement of CR and total dose >25 Gy were associated with better local control (LC) rate. Mild toxicity was experienced in 20.7% of patients. In conclusion, this study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.

AB - Background: Recent studies have reported improvement of outcomes (progression-free survival, overall survival, and prolongation of androgen deprivation treatment-free survival) with stereotactic body radiotherapy (SBRT) in non-small cell lung cancer and prostate cancer. The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of SBRT in a very large, real-world data set of patients with metastatic, persistent, and recurrent ovarian cancer (MPR-OC). Materials and Methods: The endpoints of the study were the rate of complete response (CR) to SBRT and the 24-month actuarial local control (LC) rate on “per-lesion” basis. The secondary endpoints were acute and late toxicities and the 24-month actuarial late toxicity-free survival. Objective response rate (ORR) included CR and partial response (PR). Clinical benefit (CB) included ORR and stable disease (SD). Toxicity was evaluated by the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC) and Common Terminology Criteria for Adverse Events (CTCAE) scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes. Results: CR, PR, and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions, giving a rate of CB of 96.4%. Patient aged ≤60 years, planning target volume (PTV) ≤18 cm3, lymph node disease, and biologically effective dose α/β10 > 70 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range, 3–120), the 24-month actuarial LC rate was 81.9%. Achievement of CR and total dose >25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7%) patients; of 63 side effects, 48 were grade 1, and 15 were grade 2. The 24-month late toxicity-free survival rate was 95.1%. Conclusions: This study confirms the activity and safety of SBRT in patients with MPR-OC and identifies clinical and treatment parameters able to predict CR and LC rate. Implications for Practice: This study aimed to define activity and safety of stereotactic body radiotherapy (SBRT) in a very large, real life data set of patients with metastatic, persistent, recurrent ovarian cancer (MPR-OC). Patient age 70 Gy were associated with higher chance of complete response (CR). Achievement of CR and total dose >25 Gy were associated with better local control (LC) rate. Mild toxicity was experienced in 20.7% of patients. In conclusion, this study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.

KW - Oligometastasis

KW - Oligorecurrences

KW - Ovarian cancer

KW - Personalized medicine

KW - Stereotactic body radiotherapy

KW - Stereotactic radiosurgery

U2 - 10.1634/theoncologist.2019-0309

DO - 10.1634/theoncologist.2019-0309

M3 - Article

JO - Oncologist

JF - Oncologist

SN - 1083-7159

ER -